We are live on ! Find out more
PRDS

Pardes Biosciences, Inc. Common Stock
PRDS

Delisted

PRDS was delisted on the 30th of August, 2023.

Back to rankings

Fund managers haven’t disclosed any holdings of PRDS yet.

PRDS Hedge Fund Activity: Q4 2023 in Review

0 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Pardes Biosciences, Inc. Common Stock (PRDS) for Q4 2023, worth a combined $0 — down 100% from $66.7K a quarter earlier.

Sellers outnumbered buyers: 1 fund closed out of PRDS and 0 opened new positions — a net loss of 1 holder — while 0 trimmed existing stakes and 0 added.

The largest seller was Barclays, exiting entirely with an estimated $66.7K sold.

  • 0 institutional investors held Pardes Biosciences, Inc. Common Stock (PRDS) as of Q4 2023, down from 1 in Q3 2023.
  • Funds reported $0 of Pardes Biosciences, Inc. Common Stock stock for Q4 2023, down 100% quarter-over-quarter.
  • 0 funds opened new Pardes Biosciences, Inc. Common Stock positions in Q4 2023 and 1 closed out, a net change of -1 holder.
  • The largest Pardes Biosciences, Inc. Common Stock seller in Q4 2023 was Barclays, an estimated $66.7K sold.

Based on aggregated 13F filings for Q4 2023.